A Clinical Review on Extreme Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer Using Nonrobotic Linear Accelerators

Abstract

Seven phase I–II studies fell within the inclusion criteria. Details on the radiotherapy technique, patient selection, fractionation scheme, exclusion criteria, treatment toxicity, quality-of-life, and tumor control were collected. The studies provide encouraging results of acute and late toxicity, with rare grade 3 events, that seem comparable to robotic SBRT. The biochemical disease-free survival rates look promising, but most patients belong to the low-risk group. The trials are limited by a short follow-up, small number of patients, and different approaches in prescribing dose and defining the acceptable dose heterogeneities. Currently, nonrobotic SBRT regimens should be used in the context of clinical trials.

Keywords: :

• Bladder and prostate cancer
• Clinical trials
• Radiation oncology
• Outcomes research
• Extreme hypofractionation